Announcements Trials
Browse Landscape

Phase

Phase 3 17Phase 2 16Phase 1 14Phase NA 4Phase 1/2 4Phase 2/3 3Phase EARLY_PHASE1 1

Status

Completed 8Unknown 5Recruiting 4Not yet recruiting 3Active not recruiting 2Terminated 1Enrolling by invitation 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 3Head & Neck 1

Conditions

Colorectal Neoplasms 2Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Esophageal Neoplasms 1Colonic Neoplasms 1CRC 1

Interventions

pembrolizumab 109Cyclophosphamide 85fludarabine 67Carboplatin 59Injections 58Bevacizumab 52Specimen Handling 42Gemcitabine 41Paclitaxel 40Magnetic Resonance Spectroscopy 40venetoclax 38Nivolumab 38Cisplatin 37Dexamethasone 35Biopsy 34Temozolomide 31Docetaxel 29atezolizumab 27Oxaliplatin 26Capecitabine 26Pemetrexed 25Fluorouracil 25toripalimab 24abemaciclib 24Irinotecan 24Azacitidine 24Fulvestrant 23Rituximab 21fludarabine phosphate 20durvalumab 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1/2 × Recruiting × Folfox protocol × Clear all
NCT06598007 2026-05-19

A Study to Determine the Effect of CT3001 in Patients With Advanced Solid Tumors

Crossignal Therapeutics, Inc.

Phase 1/2 Recruiting
78 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT07204574 2025-10-02

The Phase 1b/IIa, Open-label, Dose Escalation and Dose Expansion to Evaluate Safety, Tolerability, and Preliminary Efficacy of the Combination of HCB101, Cetuximab/Bevacizumab, and FOLFOX/FOLFIRI in Advanced or Metastatic Colorectal Cancer

Chang Gung Memorial Hospital

Phase 1/2 Recruiting
40 enrolled

CRC

NCT03526835 2025-01-29

A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

Merus B.V.

Phase 1/2 Recruiting
523 enrolled
GastrointestinalHead & Neck

Squamous Cell Carcinoma of Head and Neck, Esophageal Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT03985891 2020-12-17

JSFOL

Xiangya Hospital of Central South University

Phase 1/2 Recruiting
40 enrolled
Gastrointestinal

Colonic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡